

Janssen Inc. is excited to announce that...

INVOKANA[®] is the #1-Dispensed SGLT2i as Prescribed by Nephrologists in Canada^{1*}

INVOKANA[®] (canagliflozin) is indicated for monotherapy as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus for whom metformin is inappropriate due to contraindications or intolerance.²

INVOKANA[®] is also indicated for use in adult patients with type 2 diabetes mellitus to improve glycemic control in combination with:

- metformin
- sulfonylurea (with or without metformin)
- pioglitazone with metformin
- metformin and sitagliptin
- insulin (with or without metformin)

when the therapies listed here, along with diet and exercise, do not provide adequate glycemic control.²

INVOKANA[®] is also indicated as an adjunct to diet, exercise and standard-of-care therapy to reduce the risk of major adverse cardiovascular events (CV death, nonfatal MI and nonfatal stroke) in adults with type 2 diabetes mellitus and established CVD.²

SGLT2i=sodium-glucose co-transporter 2 inhibitor; CV=cardiovascular; MI=myocardial infarction;
CVD=cardiovascular disease.

* Based on data for total number of dispensed prescriptions (TRx) for SGLT2 inhibitors among nephrologists only, from the IMS Health, Canadian CompuScript Database, June–November 2019.

The logo for Invokana, featuring the brand name in a bold, sans-serif font with a stylized 'V' that has three horizontal lines above it. Below the brand name, the text 'canagliflozin tablets' is written in a smaller, lowercase, sans-serif font. The entire logo is set against a white background with a red border.

Invokana[®]
canagliflozin tablets

INVOKANA® is also NOW indicated as an adjunct to diet, exercise and standard-of-care therapy to reduce the risk of end-stage kidney disease, doubling of serum creatinine, and CV death in adult patients with type 2 diabetes mellitus and diabetic nephropathy with albuminuria (>33.9 mg/mmol).²



Please consult the Product Monograph available at www.janssen.com/canada/products for important information relating to clinical use, contraindications, serious warnings and precautions, adverse reactions, drug interactions, and dosage and administration that has not been discussed in this piece.

The Product Monograph is also available by calling us at 1-800-567-3331.

CV=cardiovascular.

References: **1.** IMS Health, Canadian CompuScript Database. June–November 2019. **2.** INVOKANA® Product Monograph. Janssen Inc. January 23, 2020.

**Invokana**[®]
canagliflozin tablets

Janssen Inc. 19 Green Belt Drive | Toronto, Ontario | M3C 1L9 | www.janssen.com/canada

© 2020 Janssen Inc. | All trademarks used under license. | CP-144481E

 MEMBER OF
INNOVATIVE MEDICINES CANADA

 PAAB 

janssen 
PHARMACEUTICAL COMPANIES OF
Johnson & Johnson